Iron Absorption From IFA and MMS Supplements in Kenyan Women During the Second Trimester of Pregnancy

Recruiting now · Not applicable

Conditions studied: Pregnancy

In brief

This study evaluates iron absorption from three antenatal supplements, 30 mg MMS, 60 mg MMS, and 60 mg IFA, in 50 pregnant Kenyan women in their second trimester. Using a randomized crossover design and stable iron isotopes, we will compare bioavailability in both fasted and fed states. Additionally, the trial will investigate if daily dosing triggers a hepcidin response that inhibits subsequent absorption, testing whether alternate-day dosing is a more effective strategy for treating iron deficiency.

Key facts

Study ID

NCT07435766

Run by

ETH Zurich

People needed

50

Starts

2026-03-02

Expected to finish

2026-12-31

Last updated by the study team

2026-02-27

Who can join

Age: 18 and older, up to 35. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• female
• pregnant at gestational age 12 (±1) weeks (dated by ultrasound)
• age 18 to 35 y
• Hb concentration ≥80 g/L
• absence of significant inflammation
• body weight <80 kg
• no major chronic diseases
• no intake of vitamin and mineral supplements outside of this study in the 1-2 weeks between screening and study start and during the study
• no blood transfusion, blood donation, or significant blood loss over the past 4 months

You may not qualify if…

• severe anemia (defined as Hb <80 g/L)
• malaria
• sickle cell disease (SS and SC)
• hemoglobin C disease (CC).

Where it is running

• Kwale Sub County Hospital — Kwale, Kwale County, Kenya (enrolling)
• Msambweni County Referral Hospital — Msambweni, Kwale County, Kenya (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.